Karyopharm Therapeutics Inc.
Organization details
- Legal name
- Karyopharm Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Newton
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- KPTI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001503802
- EIN
- 26-3931704
Board of directors
-
Barry E. Greene · DirectorSince 2023
-
Chen Schor · DirectorSince 2023
- Since 2023
-
Deepika Pakianathan · DirectorSince 2023
-
Garen G. Bohlin · DirectorSince 2023
-
Mansoor Raza Mirza · DirectorSince 2023
-
Peter Honig · DirectorSince 2023
-
Richard A. Paulson · Director · President and CEOSince 2023
-
Zhen Su · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
78.4%
-
92.7%
Board connections
7 of this board's directors also sit on 12 other boards. 12 are in the same sector.
-
Adicet Bio Inc. Same sectorvia Chen Schor
-
Bicara Therapeutics Inc. Same sectorvia Christy J. Oliger
-
City Therapeutics Inc. Same sectorvia Barry E. Greene
-
Collegium Pharmaceutical Inc. Same sectorvia Garen G. Bohlin
-
CytomX Therapeutics Inc. Same sectorvia Zhen Su
-
Dyne Therapeutics Inc. Same sectorvia Barry E. Greene
-
Freenome Inc. Same sectorvia Deepika Pakianathan
-
Mereo BioPharma Group plc Same sectorvia Deepika Pakianathan
-
Replimune Group Inc. Same sectorvia Christy J. Oliger
-
Sera Prognostics Inc. Same sectorvia Mansoor Raza Mirza
-
Vera Therapeutics Inc. Same sectorvia Christy J. Oliger
-
Zenas BioPharma Inc. Same sectorvia Christy J. Oliger
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $351,422
- 21 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 16, 2026 | Abate Kristin Officer (Chief Accounting Officer) | Open-market sale | −4,788 | $0.34 | $1,647 |
| Oct 1, 2026 | Abate Kristin Officer (Chief Accounting Officer) | Open-market sale | −378 | $1.19 | $450 |
| Sep 1, 2026 | Abate Kristin Officer (Chief Accounting Officer) | Open-market sale | −19 | $2.02 | $38 |
| Jul 28, 2026 | Poulton Stuart Officer (EVP, Chief Development Officer) | Open-market sale | −189 | $7.10 | $1,342 |
| May 21, 2026 | Christy J. Oliger Director | Grant or award | +15,508 | — | — |
| May 21, 2026 | Deepika Pakianathan Director | Grant or award | +15,508 | — | — |
| May 21, 2026 | Chen Schor Director | Grant or award | +15,508 | — | — |
| May 21, 2026 | Zhen Su Director | Grant or award | +15,508 | — | — |
| May 21, 2026 | Garen G. Bohlin Director | Grant or award | +15,508 | — | — |
| May 21, 2026 | Barry E. Greene Director | Grant or award | +15,508 | — | — |
| May 14, 2026 | Poulton Stuart Officer (EVP, Chief Development Officer) | Open-market sale | −403 | $9.50 | $3,829 |
| May 14, 2026 | Rangwala Reshma Officer (EVP & Chief Medical Officer) | Open-market sale | −408 | $9.50 | $3,876 |
| May 14, 2026 | Cheng Sohanya Roshan Officer (EVP & Chief Commercial Officer) | Open-market sale | −324 | $9.50 | $3,078 |
| May 14, 2026 | Abate Kristin Officer (Chief Accounting Officer) | Open-market sale | −53 | $9.50 | $504 |
| May 14, 2026 | Richard A. Paulson Director, Officer (President and CEO) | Open-market sale | −2,203 | $9.50 | $20,929 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Karyopharm Therapeutics Inc.
Who is the CEO of Karyopharm Therapeutics Inc.?
Richard A. Paulson is Karyopharm Therapeutics Inc.'s President and CEO.
How many directors are on Karyopharm Therapeutics Inc.'s board?
Karyopharm Therapeutics Inc.'s board has 9 directors: Barry E. Greene, Chen Schor, Christy J. Oliger, Deepika Pakianathan, Garen G. Bohlin, Mansoor Raza Mirza, Peter Honig, Richard A. Paulson and Zhen Su.
Are Karyopharm Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Karyopharm Therapeutics Inc. insiders made no open-market purchases and sold $351,422 of shares in 21 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="karyopharm-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.